These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 30193866)

  • 1. Pharmacological approach and adherence to treatment recommendations in frequently and non-frequently exacerbating COPD patients from Italy: MISTRAL - The prospective cohort, observational study.
    Scalone G; Nava S; Ventrella F; Bussoli G; Catapano GA; Pennisi A; Dadduzio F; Schino P; Pela R; Bartezaghi M; Morini P; Porpiglia PA; Muscianisi E;
    Pulm Pharmacol Ther; 2018 Dec; 53():68-77. PubMed ID: 30193866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study.
    Casas A; Montes de Oca M; Menezes AM; Wehrmeister FC; Lopez Varela MV; Mendoza L; Ramírez L; Miravitlles M
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1545-1556. PubMed ID: 29785104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Effectiveness of Long-Acting Beta
    Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA
    Pharmacotherapy; 2017 Apr; 37(4):447-455. PubMed ID: 28226405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GOLD 2017 treatment pathways in 'real life': An analysis of the DACCORD observational study.
    Worth H; Buhl R; Criée CP; Kardos P; Lossi NS; Vogelmeier CF
    Respir Med; 2017 Oct; 131():77-84. PubMed ID: 28947047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids.
    Asche CV; Leader S; Plauschinat C; Raparla S; Yan M; Ye X; Young D
    Int J Chron Obstruct Pulmon Dis; 2012; 7():201-9. PubMed ID: 22500120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study.
    Suissa S; Dell'Aniello S; Ernst P
    Lancet Respir Med; 2018 Nov; 6(11):855-862. PubMed ID: 30343028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy.
    Mapel D; Laliberté F; Roberts MH; Sama SR; Sundaresan D; Pilon D; Lefebvre P; Duh MS; Patel J
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1825-1836. PubMed ID: 28684905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors influencing treatment escalation from long-acting muscarinic antagonist monotherapy to triple therapy in patients with COPD: a retrospective THIN-database analysis.
    Hurst JR; Dilleen M; Morris K; Hills S; Emir B; Jones R
    Int J Chron Obstruct Pulmon Dis; 2018; 13():781-792. PubMed ID: 29551894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns.
    Price D; West D; Brusselle G; Gruffydd-Jones K; Jones R; Miravitlles M; Rossi A; Hutton C; Ashton VL; Stewart R; Bichel K
    Int J Chron Obstruct Pulmon Dis; 2014; 9():889-904. PubMed ID: 25210450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cross-sectional survey of current treatment and symptom burden of patients with COPD consulting for routine care according to GOLD 2014 classifications.
    Ding B; Small M; Holmgren U
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1527-1537. PubMed ID: 28579771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-life evaluation of COPD treatment in a Bulgarian population: a 1-year prospective, observational, noninterventional study.
    Ivanov Y; Nikolaev I; Nemeth I
    Int J Chron Obstruct Pulmon Dis; 2018; 13():653-663. PubMed ID: 29503539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK.
    Brusselle G; Price D; Gruffydd-Jones K; Miravitlles M; Keininger DL; Stewart R; Baldwin M; Jones RC
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2207-17. PubMed ID: 26527869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Effects of LAMA-LABA-ICS vs LAMA-LABA for COPD: Cohort Study in Real-World Clinical Practice.
    Suissa S; Dell'Aniello S; Ernst P
    Chest; 2020 Apr; 157(4):846-855. PubMed ID: 31759966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical characteristics and medication patterns in patients with COPD prior to initiation of triple therapy with ICS/LAMA/LABA: A retrospective study.
    Bogart M; Stanford RH; Reinsch T; Hull M; Buikema A; Hulbert E
    Respir Med; 2018 Sep; 142():73-80. PubMed ID: 30170806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic impact of delaying initiation with multiple-inhaler maintenance triple therapy in Spanish patients with chronic obstructive pulmonary disease.
    Sicras Mainar A; Huerta A; Navarro Artieda R; Monsó E; Landis SH; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2121-2129. PubMed ID: 31571848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhaled treatment of COPD: a Delphi consensus statement.
    Ninane V; Corhay JL; Germonpré P; Janssens W; Joos GF; Liistro G; Vincken W; Gurdain S; Vanvlasselaer E; Lehouck A
    Int J Chron Obstruct Pulmon Dis; 2017; 12():793-801. PubMed ID: 28293106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Long-Acting Muscarinic Antagonist/Long-Acting β
    Petite SE
    Ann Pharmacother; 2017 Aug; 51(8):696-705. PubMed ID: 28410560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment patterns in patients with stable COPD in China: analysis of a prospective, 52-week, nationwide, observational cohort study (REAL).
    Yang T; Cai B; Cao B; Kang J; Wen F; Chen Y; Jian W; Wang C
    Ther Adv Respir Dis; 2023; 17():17534666231158283. PubMed ID: 37013442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COPD exacerbation frequency, pharmacotherapy and resource use: an observational study in UK primary care.
    Thomas M; Radwan A; Stonham C; Marshall S
    COPD; 2014 Jun; 11(3):300-9. PubMed ID: 24152210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initiation of triple therapy maintenance treatment among patients with COPD in the US.
    Simeone JC; Luthra R; Kaila S; Pan X; Bhagnani TD; Liu J; Wilcox TK
    Int J Chron Obstruct Pulmon Dis; 2017; 12():73-83. PubMed ID: 28053518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.